Form 4: Adverum Biotechnologies Director's Options Cancelled Post-Merger

A director of Adverum Biotechnologies reported the cancellation and cash-out of stock options following the company's acquisition by Eli Lilly and Company.

Summary

• Adverum Biotechnologies, Inc. was acquired by Eli Lilly and Company's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, with the merger becoming effective on December 9, 2025.
• Tendering stockholders received $3.56 per share in cash (Cash Consideration) and one non-tradable Contingent Value Right (CVR) for each share.
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling up to $8.91 per CVR, net to the stockholder, upon the achievement of specified milestones.
• Director Szilard Kiss's stock options with an exercise price equal to or greater than the Cash Consideration ($3.56) were fully vested prior to the merger and then cancelled for no consideration.
• Director Szilard Kiss's stock options with an exercise price less than the Cash Consideration ($3.56) were automatically cancelled, and in exchange, the holder received cash and CVRs.
• For 10,450 shares underlying options with an exercise price of $2.32, the director received $12,958 in cash and 10,450 CVRs.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, a definitive corporate event. While out-of-the-money options were cancelled, in-the-money options were cashed out, and shareholders received cash plus CVRs, indicating a structured and generally positive exit for shareholders, albeit with the uncertainty of CVRs.

Positives

• Shareholders received a definitive cash payment of $3.56 per share as part of the merger consideration.
• Shareholders also received Contingent Value Rights (CVRs) offering potential additional cash payments of up to $8.91 per CVR upon the achievement of specified milestones.
• In-the-money stock option holders, such as the reporting director, received cash and CVRs for their options, providing a financial benefit from the acquisition.

Negatives

• Stock options with an exercise price equal to or greater than the Cash Consideration ($3.56) were cancelled for no consideration, resulting in a loss of potential value for those option holders.
• The company's common stock is no longer publicly traded, removing it as an investment opportunity in the public market.
• The CVRs are non-tradable, limiting liquidity for holders who may wish to exit their position before milestones are achieved.

Risks

• The contingent cash payments from CVRs are not guaranteed and are dependent on the achievement of specified milestones, which may not occur.
• The CVRs are non-tradable, meaning holders cannot sell them on an open market and must wait for milestone achievements for potential payment.
• Any payments received from the cash consideration or CVRs are subject to applicable tax withholding.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company, and its common stock is no longer publicly traded. Future performance will be integrated into Eli Lilly's financial reporting. The Contingent Value Rights (CVRs) offer potential future payments to former shareholders based on the achievement of specified milestones.

Industry Context

This acquisition by Eli Lilly and Company, a major pharmaceutical firm, underscores the ongoing trend of consolidation within the biotechnology sector. Larger companies frequently acquire smaller biotechs to expand their therapeutic pipelines, gain access to innovative platforms, or eliminate competition. The use of Contingent Value Rights (CVRs) in the deal structure is a common mechanism in biotech M&A to manage risk and reward, particularly when the acquired assets have future clinical or regulatory milestones.

Comparison to Industry Standards

• The structure of the acquisition, involving a cash component and Contingent Value Rights (CVRs), aligns with common practices in biotech mergers, where CVRs are used to bridge valuation gaps and share future development risks, similar to deals involving milestone payments for drug approvals or sales targets.
• The treatment of stock options, specifically the cancellation of out-of-the-money options for no consideration and the cash-out of in-the-money options based on the difference between the acquisition price and exercise price, is standard procedure in corporate mergers and acquisitions across industries.
• The reporting person's cessation of Section 16 reporting obligations is a typical outcome when a public company becomes a private subsidiary, as insider trading rules for public companies no longer apply to the same extent.

Management Changes

Corporate Governance

Related Party Transactions

• The merger itself constitutes a related party transaction, as Adverum Biotechnologies, Inc. was acquired by Flying Tigers Acquisition Corporation, a direct wholly owned subsidiary of Eli Lilly and Company.

Stakeholder Impact

• Shareholders: Their direct equity ownership in Adverum Biotechnologies ceased, replaced by cash consideration and non-tradable CVRs.
• Employees: Adverum employees are now part of the Eli Lilly and Company organization.
• Management/Directors: The reporting person (Szilard Kiss) is no longer subject to Section 16 reporting, reflecting the company's change in status.

Next Steps

• Monitoring the achievement of specified milestones that would trigger contingent cash payments for CVR holders.
• Integration of Adverum Biotechnologies into Eli Lilly and Company's operations.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Stock Options, Contingent Value Rights, CVR, Tender Offer, Insider Transaction, Form 4